Skip to main
ICLR
ICLR logo

ICON (ICLR) Stock Forecast & Price Target

ICON (ICLR) Analyst Ratings

Based on 25 analyst ratings
Buy
Strong Buy 32%
Buy 24%
Hold 44%
Sell 0%
Strong Sell 0%

Bulls say

Icon, as a leading late-stage contract research organization, demonstrates a robust financial outlook driven by a favorable industry landscape characterized by increased trial outsourcing, consolidation in the pharmaceutical sector, and rising R&D budgets. The successful acquisition of PRA has not only strengthened Icon's portfolio in early-phase and biotech services but also positioned the company to meet or exceed financial targets, showcasing operational efficiency. Additionally, Icon's commitment to gender parity at higher management levels reflects a progressive corporate ethos that can potentially enhance its reputation and attractiveness to clients in a competitive market.

Bears say

The outlook for Icon's stock appears negative due to a reported slower recovery in the biotech sector, with expectations of weakness in the first half of 2025 before any potential growth in the latter half. Additionally, the company's book-to-bill ratio has stagnated, failing to meet prior expectations and suggesting reduced demand for its services in the upcoming quarters. Compounded by a challenging macroeconomic environment affecting customer access to capital, these factors indicate that Icon may face headwinds in achieving projected growth, which could negatively impact its earnings and overall financial performance.

ICON (ICLR) has been analyzed by 25 analysts, with a consensus rating of Buy. 32% of analysts recommend a Strong Buy, 24% recommend Buy, 44% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ICON and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ICON (ICLR) Forecast

Analysts have given ICON (ICLR) a Buy based on their latest research and market trends.

According to 25 analysts, ICON (ICLR) has a Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $190.24, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $190.24, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ICON (ICLR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.